Citadel Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $445K | Buy |
20,000
+8,000
| +67% | +$191K | ﹤0.01% | 9575 |
|
|
2025
Q4 | $321K | Sell |
12,000
-66,900
| -85% | -$1.6M | ﹤0.01% | 9988 |
|
|
2025
Q3 | $1.68M | Buy |
78,900
+25,800
| +49% | +$610K | ﹤0.01% | 6428 |
|
|
2025
Q2 | $1.15M | Sell |
53,100
-26,400
| -33% | -$491K | ﹤0.01% | 6779 |
|
|
2025
Q1 | $1.32M | Buy |
79,500
+10,700
| +16% | +$194K | ﹤0.01% | 6337 |
|
|
2024
Q4 | $1.26M | Sell |
68,800
-11,200
| -14% | -$181K | ﹤0.01% | 6552 |
|
|
2024
Q3 | $1.23M | Sell |
80,000
-9,700
| -11% | -$162K | ﹤0.01% | 6437 |
|
|
2024
Q2 | $1.46M | Buy |
89,700
+8,400
| +10% | +$136K | ﹤0.01% | 5883 |
|
|
2024
Q1 | $1.5M | Buy |
81,300
+300
| +0.4% | +$7.43K | ﹤0.01% | 6079 |
|
|
2023
Q4 | $2.54M | Sell |
81,000
-800
| -1% | -$19.1K | ﹤0.01% | 4957 |
|
|
2023
Q3 | $1.7M | Buy |
81,800
+51,900
| +174% | +$1.41M | ﹤0.01% | 5516 |
|
|
2023
Q2 | $716K | Sell |
29,900
-6,500
| -18% | -$144K | ﹤0.01% | 7143 |
|
|
2023
Q1 | $685K | Sell |
36,400
-86,200
| -70% | -$1.64M | ﹤0.01% | 7626 |
|
|
2022
Q4 | $1.95M | Sell |
122,600
-25,500
| -17% | -$399K | ﹤0.01% | 5538 |
|
|
2022
Q3 | $2.42M | Sell |
148,100
-309,100
| -68% | -$5.01M | ﹤0.01% | 5222 |
|
|
2022
Q2 | $6.44M | Buy |
457,200
+325,900
| +248% | +$6.08M | ﹤0.01% | 3349 |
|
|
2022
Q1 | $3.18M | Sell |
131,300
-91,500
| -41% | -$2.21M | ﹤0.01% | 5043 |
|
|
2021
Q4 | $5.2M | Buy |
222,800
+9,000
| +4% | +$181K | ﹤0.01% | 4221 |
|
|
2021
Q3 | $3.55M | Buy |
213,800
+10,900
| +5% | +$210K | ﹤0.01% | 4995 |
|
|
2021
Q2 | $4.95M | Sell |
202,900
-33,500
| -14% | -$756K | ﹤0.01% | 4455 |
|
|
2021
Q1 | $6.1M | Buy |
236,400
+131,200
| +125% | +$5.78M | ﹤0.01% | 3839 |
|
|
2020
Q4 | $5.62M | Sell |
105,200
-800
| -0.8% | -$39.7K | ﹤0.01% | 3494 |
|
|
2020
Q3 | $4.37M | Sell |
106,000
-56,800
| -35% | -$2.45M | ﹤0.01% | 3350 |
|
|
2020
Q2 | $7.89M | Buy |
162,800
+44,400
| +38% | +$2.13M | ﹤0.01% | 2502 |
|
|
2020
Q1 | $5M | Sell |
118,400
-155,000
| -57% | -$6.39M | ﹤0.01% | 2702 |
|
|
2019
Q4 | $11.7M | Sell |
273,400
-45,200
| -14% | -$1.97M | 0.01% | 2038 |
|
|
2019
Q3 | $11.5M | Buy |
318,600
+202,800
| +175% | +$6.15M | 0.01% | 2061 |
|
|
2019
Q2 | $3.1M | Buy |
115,800
+38,900
| +51% | +$994K | ﹤0.01% | 3800 |
|
|
2019
Q1 | $2.06M | Sell |
76,900
-124,100
| -62% | -$2.9M | ﹤0.01% | 4410 |
|
|
2018
Q4 | $3.25M | Sell |
201,000
-44,800
| -18% | -$870K | ﹤0.01% | 3401 |
|
|
2018
Q3 | $5.1M | Buy |
245,800
+149,500
| +155% | +$2.35M | ﹤0.01% | 2979 |
|
|
2018
Q2 | $1.47M | Buy |
96,300
+28,800
| +43% | +$514K | ﹤0.01% | 4576 |
|
|
2018
Q1 | $1.52M | Sell |
67,500
-3,000
| -4% | -$83.1K | ﹤0.01% | 4157 |
|
|
2017
Q4 | $2.12M | Buy |
70,500
+2,900
| +4% | +$92.7K | ﹤0.01% | 3556 |
|
|
2017
Q3 | $2.55M | Sell |
67,600
-1,500
| -2% | -$48.8K | ﹤0.01% | 3122 |
|
|
2017
Q2 | $1.93M | Sell |
69,100
-6,400
| -8% | -$191K | ﹤0.01% | 3215 |
|
|
2017
Q1 | $2.6M | Sell |
75,500
-105,700
| -58% | -$3.73M | ﹤0.01% | 2754 |
|
|
2016
Q4 | $5.23M | Buy |
181,200
+95,500
| +111% | +$2.53M | 0.01% | 1953 |
|
|
2016
Q3 | $2.73M | Sell |
85,700
-59,500
| -41% | -$2.02M | ﹤0.01% | 2606 |
|
|
2016
Q2 | $4.71M | Sell |
145,200
-52,700
| -27% | -$1.76M | 0.01% | 1867 |
|
|
2016
Q1 | $5.53M | Buy |
197,900
+50,000
| +34% | +$1.09M | 0.01% | 1668 |
|
|
2015
Q4 | $5.27M | Buy |
147,900
+54,000
| +58% | +$1.9M | 0.01% | 1774 |
|
|
2015
Q3 | $3.1M | Sell |
93,900
-32,000
| -25% | -$1.33M | ﹤0.01% | 2426 |
|
|
2015
Q2 | $5.27M | Sell |
125,900
-60,200
| -32% | -$2.33M | ﹤0.01% | 2018 |
|
|
2015
Q1 | $6.07M | Buy |
186,100
+38,600
| +26% | +$1.33M | 0.01% | 1837 |
|
|
2014
Q4 | $4.68M | Sell |
147,500
-7,000
| -5% | -$199K | ﹤0.01% | 2043 |
|
|
2014
Q3 | $3.83M | Buy |
154,500
+27,600
| +22% | +$645K | ﹤0.01% | 2226 |
|
|
2014
Q2 | $2.87M | Sell |
126,900
-38,400
| -23% | -$802K | ﹤0.01% | 2377 |
|
|
2014
Q1 | $4.02M | Buy |
165,300
+44,000
| +36% | +$1.11M | ﹤0.01% | 1973 |
|
|
2013
Q4 | $3.03M | Buy |
121,300
+40,900
| +51% | +$965K | ﹤0.01% | 2135 |
|
|
2013
Q3 | $2.21M | Sell |
80,400
-7,800
| -9% | -$163K | ﹤0.01% | 2322 |
|
|
2013
Q2 | $1.6M | Buy |
+88,200
| New | +$1.21M | ﹤0.01% | 2699 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Citadel Advisors's ACAD Position: Q1 2026 in Review
Citadel Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 54% in Q1 2026, selling an estimated $17.8M and leaving 622,760 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2784.
Citadel Advisors first reported a position in ACAD in Q2 2013 and has held it in 51 quarters since. The position peaked at $187M in Q2 2020. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Citadel Advisors held 622,760 shares of Acadia Pharmaceuticals worth $13.9M as of Q1 2026.
- Citadel Advisors sold 744,699 Acadia Pharmaceuticals shares in Q1 2026, an estimated $17.8M.
- Acadia Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2784 holding.
- Citadel Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Acadia Pharmaceuticals position peaked at $187M in Q2 2020.
- 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.